US Bancorp
KRYS icon

US Bancorp’s Krystal Biotech KRYS Stock Holding History

US Bancorp’s Portfolio KRYS Stock Details KRYS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$93.3K Buy
251
+17
+7% +$5.08K ﹤0.01% 2495
2026
Q1 		$60.4K Sell
234
-79
-25% -$21K ﹤0.01% 2630
2025
Q4 		$77.2K Buy
313
+3
+1% +$631 ﹤0.01% 2498
2025
Q3 		$54.7K Sell
310
-194
-38% -$29K ﹤0.01% 2632
2025
Q2 		$69.3K Sell
504
-135
-21% -$19.8K ﹤0.01% 2626
2025
Q1 		$115K Sell
639
-388
-38% -$65.3K ﹤0.01% 2330
2024
Q4 		$161K Buy
1,027
+82
+9% +$14.5K ﹤0.01% 2133
2024
Q3 		$172K Sell
945
-818
-46% -$158K ﹤0.01% 2106
2024
Q2 		$324K Sell
1,763
-34
-2% -$5.71K ﹤0.01% 1752
2024
Q1 		$320K Buy
1,797
+173
+11% +$24K ﹤0.01% 1771
2023
Q4 		$201K Buy
1,624
+1,435
+759% +$159K ﹤0.01% 2006
2023
Q3 		$21.9K Hold
189
– – ﹤0.01% 2833
2023
Q2 		$22.2K Buy
189
+10
+6% +$1.02K ﹤0.01% 2926
2023
Q1 		$14.3K Sell
179
-13
-7% -$1.02K ﹤0.01% 3151
2022
Q4 		$15.2K Sell
192
-48
-20% -$3.56K ﹤0.01% 3137
2022
Q3 		$17K Sell
240
-166
-41% -$12K ﹤0.01% 3109
2022
Q2 		$27K Sell
406
-265
-39% -$16.5K ﹤0.01% 2892
2022
Q1 		$45K Sell
671
-164
-20% -$10.2K ﹤0.01% 2681
2021
Q4 		$58K Buy
835
+725
+659% +$42.2K ﹤0.01% 2569
2021
Q3 		$6K Buy
110
+16
+17% +$947 ﹤0.01% 3589
2021
Q2 		$6K Sell
94
-111
-54% -$7.75K ﹤0.01% 3565
2021
Q1 		$16K Hold
205
– – ﹤0.01% 3120
2020
Q4 		$12K Hold
205
– – ﹤0.01% 3110
2020
Q3 		$9K Hold
205
– – ﹤0.01% 3118
2020
Q2 		$8K Buy
+205
New +$9.86K ﹤0.01% 3162

Other funds holding KRYS

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
SCM
Soleus Capital Management Greenwich, Connecticut $2.9B AUM 169.69% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

US Bancorp's KRYS Position: Q2 2026 in Review

US Bancorp increased its Krystal Biotech (KRYS) stake by 7.3% in Q2 2026, buying an estimated $5.08K and bringing the position to 251 shares worth $93.3K. The position accounts for ﹤0.01% of the portfolio, ranked #2495.

US Bancorp first reported a position in KRYS in Q2 2020 and has held it in 25 quarters since. The position peaked at $324K in Q2 2024. 423 funds tracked by Wall St. Rank hold KRYS as of Q2 2026.

  • US Bancorp held 251 shares of Krystal Biotech worth $93.3K as of Q2 2026.
  • US Bancorp bought 17 Krystal Biotech shares in Q2 2026, an estimated $5.08K.
  • Krystal Biotech made up ﹤0.01% of US Bancorp's portfolio in Q2 2026, its #2495 holding.
  • US Bancorp first reported a position in Krystal Biotech in Q2 2020 and has held it in 25 quarters since.
  • US Bancorp's Krystal Biotech position peaked at $324K in Q2 2024.
  • 423 funds tracked by Wall St. Rank held Krystal Biotech as of Q2 2026.

Based on US Bancorp's 13F filing for Q2 2026, filed 12 Aug 2026.